Anavex Life Sciences Corp.
AVXL
$2.76
-$0.09-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -188.66% | 7.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -204.86% | -4.33% | |||
| Operating Income | 204.86% | 4.33% | |||
| Income Before Tax | 246.57% | 5.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 246.57% | 6.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 246.57% | 6.04% | |||
| EBIT | 204.86% | 4.33% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 246.53% | 9.72% | |||
| Normalized Basic EPS | 246.67% | 9.55% | |||
| EPS Diluted | 238.89% | 9.72% | |||
| Normalized Diluted EPS | 246.11% | 9.55% | |||
| Average Basic Shares Outstanding | 0.02% | 4.10% | |||
| Average Diluted Shares Outstanding | 0.24% | 4.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||